AstraZeneca on Thursday appointed company insider Rick Suarez as the head of its U.S. biopharmaceuticals unit to lead the ...

Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium PresentationHOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a ...

A biopharmaceuticals company has announced a $200 million expansion in Fishers, with the expectation that in five years the ...

About Pulmocide Pulmocide Ltd ( is a late-stage biopharmaceutical company focused on the development of a novel inhaled azole therapy for patients at risk of developing serious complications ...

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the ...

Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics ...

Peptide therapeutics have progressed from insulin discovery to GLP-1 class molecules, revolutionizing diabetes treatment and ...

Prolytix, a U.S.-based bioanalytical leader, has acquired 60 validated thrombosis and hemostasis assays from Hemostasis Reference Laboratory (HRL).

Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...

It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and ...